Clinical trials: Type 2 Diabetes Mellitus 1
Type 1 Diabetes Mellitus
Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes
This is a parallel, Phase 2, two-arm study to assess the efficacy and safety of 14-days intravenous (IV) infusion of teplizumab treatment.
- Trial name
- KIBOU-T1D (NCT06791291)
- Testing
- Teplizumab
- Where
- 11 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Sanofi
Normal Healthy Volunteer, Safety After Oral Intake
A Research Study to Evaluate BLX-7006 in Healthy Adults
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection.
- Trial name
- NCT07140055
- Testing
- BLX-7006
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Gastroparesis, Diabetes Mellitus, Type 1
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
The purpose of this study is to test the safety and effectiveness of two dosage levels (10mg and 20mg) of TZP-102 compared to placebo (capsule that looks like the study drug but contains no active drug), administered once-daily…
- Conditions
- Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01452815
- Testing
- 10mg TZP-102, 20mg TZP-102
- Where
- 52 sites in United States, Belgium and 6 more
- Volunteers
- 201 people
- Sponsor
- Tranzyme, Inc.
Type 1 Diabetes
Closing the Loop in Adults With Type 1 Diabetes (CLEAR)
The main objective of this study is to determine whether home use of fully closed-loop glucose control applying ultra-rapid Lispro insulin is superior to standard insulin pump therapy with continuous glucose monitoring (CGM) in…
- Trial name
- NCT04977908
- Testing
- CamAPS HX, Standard insulin pump therapy with CGM
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University of Cambridge
Diabetes Mellitus, Type 2
Trial to Evaluate Efficacy+Safety of Revita DMR Treatment Paradigm 1 and Retreatment in Type 2 Diabetes Patients
The objective of this study is to evaluate feasibility, safety, and efficacy of endoscopic DMR Treatment Paradigm 1 (compared to sham) and to evaluate feasibility, safety, and efficacy of re-treatment with DMR at 24 weeks…
- Trial name
- REMIND (NCT06092476)
- Testing
- Revita® DMR Treatment
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Type 2 Diabetes Mellitus, Steroids
Incretin Physiology Associated With Steroid Hormone Treatment
The purpose of this study is to evaluate whether the reduced incretin effect and the paradoxical glucagon responses during oral glucose ingestion and isoglycaemic iv glucose infusion observed in patients with type 2 diabetes are…
- Trial name
- NCT00713440
- Testing
- Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Glostrup University Hospital, Copenhagen
Type 1 Diabetes, Type 2 Diabetes
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
The purpose of this study is to demonstrate point accuracy of the Abbott Sensor Based Glucose Monitoring (GM) System interstitial glucose results against Reader capillary Blood Glucose (BG) reference using the Consensus Error…
- Trial name
- NCT02073058
- Testing
- No treatment
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- Abbott Diabetes Care
Type 1 or 2 Diabetes
Therapeutic Education of the Patients Diabetics Imprisoned at the Paris Jail
A lot of data show that therapeutic education is beneficial for diabetic patients. In the French jails, there are very few programs of therapeutic education while this population is usually precarious with no access at care…
- Trial name
- EPRIDIA (NCT02159417)
- Testing
- Therapeutic Education
- Where
- 2 sites in France
- Volunteers
- 22 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetes Mellitus, Diabetes Mellitus, Type 1
Post Approval Study of the Eversense® Continuous Glucose Monitoring
A Post Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System over repeat insertion and removal cycles and to demonstrate the long-term safety of the…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PAS (NCT03908125)
- Testing
- Eversense® CGM System
- Where
- 17 sites in United States
- Volunteers
- 273 people
- Sponsor
- Senseonics, Inc.
Diabetes Mellitus Type 2
The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion
Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in the treatment of DM2 (type 2 diabetes mellitus).
- Trial name
- NCT02796950
- Testing
- Acipimox
- Where
- Denmark
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Diabetes, Type 1 Diabetes Mellitus
Efficacy of Closed-Loop Strategy With and Without a Learning Component in Children and Adolescents With Type 1 Diabetes at a Diabetes Camp
Our lab has developed an artificial pancreas system called the McGill Artificial Pancreas (MAP) for automating insulin delivery.
- Trial name
- NCT03581968
- Testing
- Artificial Pancreas
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- McGill University
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Effectiveness and Safety Study of the Abbott Sensor Based Glucose Monitoring Systems
The purpose of the study is to evaluate the safety and effectiveness of the Abbott Sensor Based Glucose Monitoring System Personal (System-P) and Abbott Sensor Based Glucose Monitoring System Professional (System-Pro) when used…
- Trial name
- NCT02283411
- Testing
- Abbott Sensor Based Glucose Monitoring System
- Where
- 6 sites in United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Abbott Diabetes Care
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
The ELG Analysis of Glucose a Correlational to Blood Glucose Assay
This study is an investigational study of the ELG medical device to monitor glucose blood level in diabetes mellitus Type 1 and 2 without blood samples in comparison to blood testing methods."Investigational" means the ELG…
- Trial name
- NCT05055804
- Testing
- ELG
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- XP Technology, LLC
Type 1 Diabetes Mellitus
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus
Primary Objective: To compare the efficacy of a new formulation of insulin glargine (HOE901-U300) to Lantus in terms of change of HbA1c from baseline to endpoint (month 6) in children and adolescents with type 1 diabetes…
- Trial name
- EDITION JUNIOR (NCT02735044)
- Testing
- Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
- Where
- 107 sites in United States, Argentina and 22 more
- Volunteers
- 463 people
- Sponsor
- Sanofi
Diabetes, Type 1 Diabetes
The Role of South Asian vs European Origins on Circulating Regenerative Cell Exhaustion
ORIGINS-RCE is an observational, cross-sectional, two-arm study aimed at determining if an individual's ethnic origin influences the number of blood vessel-forming stem cells in the bloodstream.
- Conditions
- Diabetes, Type 1 Diabetes, Type 2 Diabetes, Ischemic Heart Disease
- Trial name
- ORIGINS-RCE (NCT05253521)
- Where
- 3 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Canadian Medical and Surgical Knowledge Translation Research Group
Healthy Volunteers
A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
The purpose of this study is to assess the bioequivalence of the fixed dose combination (two components combined in one tablet) of canagliflozin and metformin extended release (XR) tablet (dose of 2 X 50 mg/500 mg) with respect…
- Trial name
- NCT02065752
- Testing
- Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/500 mg
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Type 1 Diabetes, Type 2 Diabetes
Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control
This proposal seeks to gather continuous blood glucose and physical activity data from individuals with and without diabetes.
- Trial name
- NCT02190669
- Testing
- exercise
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sansum Diabetes Research Institute
Type 1 Diabetes
Short Term Closed-loop Glucose Control in Adults With Type 1 Diabetes
The main objective of this study is to determine the feasibility, efficacy and safety of automated closed-loop glucose control in the home setting over a short term period.
- Trial name
- AP@home02 (NCT01666028)
- Testing
- FlorenceD or similar closed loop glucose control system, CSII with real-time CGM
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 18 people
- Sponsor
- University of Cambridge
Diabetes Mellitus, Type 2
A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes
The primary objective is to demonstrate, after 52 weeks of treatment, the non-inferiority of rimonabant 20 mg once daily (od) versus glimepiride od in reducing glycosylated haemoglobin (HbA1c) in overweight/obese patients with…
- Trial name
- ALLEGRO (NCT00449605)
- Testing
- Rimonabant, Glimepiride, Metformin
- Where
- 15 sites in United States, Chile and 12 more
- Volunteers
- 508 people
- Sponsor
- Sanofi
Diabetes Mellitus
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
The purpose of the study is to compare the effect in blood sugar control between Lantus and twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a multiple daily injection setting with fast…
- Trial name
- NCT00046501
- Testing
- Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.